Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2492928 | 0.97 | GPR84 (0.47) | GPR84FFAR1KDM4EDUSP3MEN1 | |
| SCHEMBL21018932 | 0.97 | GPR84 (0.47) | GPR84FFAR1KDM4EDUSP3MEN1 | |
| SCHEMBL7786148 | 0.97 | GPR84 (0.47) | GPR84FFAR1KDM4EDUSP3MEN1 | |
| SCHEMBL2502264 | 0.97 | GPR84 (0.47) | GPR84FFAR1KDM4EDUSP3MEN1 | |
| SCHEMBL7783905 | 0.97 | GPR84 (0.47) | GPR84FFAR1KDM4EDUSP3MEN1 | |
| SCHEMBL9115425 | 0.97 | GPR84 (0.47) | GPR84FFAR1KDM4EDUSP3MEN1 | |
| SCHEMBL9116790 | 0.97 | GPR84 (0.47) | GPR84FFAR1KDM4EDUSP3MEN1 | |
| SCHEMBL2500612 | 0.94 | GPR84 (0.40) | GPR84FFAR1KDM4EDUSP3MEN1 | |
| SCHEMBL2637946 | 0.89 | DGKA (0.47) | GPR84FFAR1FFAR4 | |
| SCHEMBL2637945 | 0.89 | DGKA (0.47) | GPR84FFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1534213-B1 | WATER-BASED DELIVERY SYSTEMS | SKOELD THOMAS (SE) | 2013-04-24 | — | — | EP | claimed |
| JP-4806519-B2 | — | — | 2011-11-02 | — | — | JP | claimed |
| US-20090226491-A1 | Water-based delivery systems | SKOLD, THOMAS (SE) | 2009-09-10 | — | — | US | claimed |
| US-20090081139-A1 | Water-based delivery systems | GALDERMA LABORATORIES, INC. | 2009-03-26 | — | — | US | claimed |
| WO-2006039667-A2 | WATER-BASED DELIVERY SYSTEMS | COLLAGENEX PHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | WO | claimed |
| EP-1534213-A4 | WATER-BASED DELIVERY SYSTEMS | COLLAGENEX PHARM INC (US) | 2005-10-26 | — | — | EP | claimed |
| US-20050129722-A1 | For an active substance, characterized by enhancing skin barrier restoration in the stratum corneum comprising a fatty acid, cholesterol, a ceramide and at least one skin lipid precursor; topical drug delivery | COLLAGENEX PHARMACEUTICALS, INC. | 2005-06-16 | — | — | US | claimed |
| EP-1534213-A2 | WATER-BASED DELIVERY SYSTEMS | Collagenex Pharmaceuticals, Inc. (US) | 2005-06-01 | — | — | EP | claimed |
| US-20040009213-A1 | Water-based delivery systems | COLLAGENEX PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | claimed |
| WO-2003077861-A2 | WATER-BASED DELIVERY SYSTEMS | COLLAGENEX PHARMACEUTICALS, INC. (US) | 2003-09-25 | — | — | WO | claimed |
| EP-1534213-B1 | WATER-BASED DELIVERY SYSTEMS | SKOELD THOMAS (SE) | 2013-04-24 | — | — | EP | disclosed |
| US-8029810-B2 | Water-based delivery systems | Skold, Thomas (SE) | 2011-10-04 | — | — | US | disclosed |
| US-20090226491-A1 | Water-based delivery systems | SKOLD, THOMAS (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090081139-A1 | Water-based delivery systems | GALDERMA LABORATORIES, INC. | 2009-03-26 | — | — | US | disclosed |
| WO-2006039667-A2 | WATER-BASED DELIVERY SYSTEMS | COLLAGENEX PHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| EP-0747042-B1 | Compositions containing azole derivatives for topical application to skin | UNILEVER PLC (GB) | 2002-10-02 | — | — | EP | disclosed |
| EP-0747042-A1 | Compositions containing azole derivatives for topical application to skin | UNILEVER PLC (GB) | 1996-12-11 | — | — | EP | disclosed |
| US-5582832-A | CONTAINS AN AZOLE IN COMBINATION WITH A LIPID INGREDIENT; APPLYING TO IMPROVE OR PREVENT THE APPEARANCE OF WRINKLED, FLAKY, AGED OR PHOTODAMAGED SKIN | CHESEBROUGH-POND'S USA CO., DIVISION OF CONOPCO, INC. (US) | 1996-12-10 | — | — | US | disclosed |
| EP-0711558-A1 | Compositions for topical application to skin, hair and nails | UNILEVER PLC (GB) | 1996-05-15 | — | — | EP | disclosed |
| US-5476661-A | Mixture of 25-hydroxycholecalciferol, a ceramide lipid, and a carrier; keratinocyte prodifferentiation, cosmetics | ELIZABETH ARDEN CO., DIVISION OF CONOPCO, INC. (US) | 1995-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050129722-A1 | For an active substance, characterized by enhancing skin barrier restoration in the stratum corneum comprising a fatty acid, cholesterol, a ceramide and at least one skin lipid precursor; topical drug delivery | CERT1, CERS2, SGMS1 | GPR84 568/4885FFAR1 205/4885KDM4E 4232/4885 |
| US-20090226491-A1 | Water-based delivery systems | CERS2, SGMS2, SGMS1 | GPR84 682/4885FFAR1 288/4885KDM4E 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.